BioNexus Gene Lab Stock

BioNexus Gene Lab P/S 2025

BioNexus Gene Lab P/S

0.52

Ticker

BGLC

ISIN

US0906283066

As of Aug 2, 2025, BioNexus Gene Lab's P/S ratio stood at 0.52, a -39.53% change from the 0.86 P/S ratio recorded in the previous year.

The BioNexus Gene Lab P/S history

BioNexus Gene Lab Aktienanalyse

What does BioNexus Gene Lab do?

BioNexus Gene Lab ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding BioNexus Gene Lab's P/S Ratio

BioNexus Gene Lab's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing BioNexus Gene Lab's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating BioNexus Gene Lab's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in BioNexus Gene Lab’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about BioNexus Gene Lab stock

What is the price-to-earnings ratio of BioNexus Gene Lab?

The price-earnings ratio of BioNexus Gene Lab is currently 0.52.

How has the price-earnings ratio of BioNexus Gene Lab changed compared to last year?

The price-to-earnings ratio of BioNexus Gene Lab has increased by -39.53% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of BioNexus Gene Lab high compared to other companies?

Yes, the price-to-earnings ratio of BioNexus Gene Lab is high compared to other companies.

How does an increase in the price-earnings ratio of BioNexus Gene Lab affect the company?

An increase in the price-earnings ratio of BioNexus Gene Lab would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of BioNexus Gene Lab affect the company?

A decrease in the price-earnings ratio of BioNexus Gene Lab would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of BioNexus Gene Lab?

Some factors that influence the price-earnings ratio of BioNexus Gene Lab are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does BioNexus Gene Lab pay?

Over the past 12 months, BioNexus Gene Lab paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, BioNexus Gene Lab is expected to pay a dividend of 0 USD.

What is the dividend yield of BioNexus Gene Lab?

The current dividend yield of BioNexus Gene Lab is .

When does BioNexus Gene Lab pay dividends?

BioNexus Gene Lab pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of BioNexus Gene Lab?

BioNexus Gene Lab paid dividends every year for the past 0 years.

What is the dividend of BioNexus Gene Lab?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is BioNexus Gene Lab located?

BioNexus Gene Lab is assigned to the '-' sector.

Wann musste ich die Aktien von BioNexus Gene Lab kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of BioNexus Gene Lab from 8/2/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/2/2025.

When did BioNexus Gene Lab pay the last dividend?

The last dividend was paid out on 8/2/2025.

What was the dividend of BioNexus Gene Lab in the year 2024?

In the year 2024, BioNexus Gene Lab distributed 0 USD as dividends.

In which currency does BioNexus Gene Lab pay out the dividend?

The dividends of BioNexus Gene Lab are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von BioNexus Gene Lab

Our stock analysis for BioNexus Gene Lab Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BioNexus Gene Lab Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.